PDF(Pubmed)
Abstract：
Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many of whom endure years of ineffective treatments and poor quality of life. The pathogenesis of this disease and its management remain incompletely understood. However, recent advances in the molecular characterization of the disease and identification of novel targeted therapies with activity in low-grade serous carcinoma offer the promise of improved outcomes. To update clinicians regarding recent scientific and clinical trial advancements and discuss unanswered questions related to low-grade serous carcinoma diagnosis and treatment, a panel of experts convened for a workshop in October 2022 to develop a consensus document addressing pathology, translational research, epidemiology and risk, clinical management, and ongoing research. In addition, the patient perspective was discussed. The recommendations developed by this expert panel-presented in this consensus document-will guide practitioners in all settings regarding the clinical management of women with low-grade serous carcinoma and discuss future opportunities to improve research and patient care.
摘要：
与高级别浆液性癌相比，低级别卵巢或腹膜浆液性癌是一种不太常见的上皮性卵巢癌类型，对化疗不敏感，影响年轻女性，他们中的许多人忍受了多年无效的治疗和生活质量差。这种疾病的发病机制及其管理仍未完全了解。然而,该疾病的分子表征的最新进展以及在低级别浆液性癌中具有活性的新型靶向治疗的鉴定为改善预后提供了希望。更新临床医生最近的科学和临床试验进展，并讨论与低级别浆液性癌诊断和治疗相关的未解决的问题，一个专家小组于2022年10月召开了一次研讨会，以制定一份关于病理学的共识文件，翻译研究,流行病学和风险，临床管理，和正在进行的研究。此外,讨论了患者的观点。该专家小组在本共识文件中提出的建议将指导从业人员在所有情况下对低级别浆液性癌妇女的临床管理，并讨论改善研究和患者护理的未来机会。
